Speaker line-up of 2023
Amir Nakar
Scientific Affairs Specialist, MeMed
Anand Anandkumar
Chief Executive Officer, Bugworks Research Inc.
Anders Karlén
Professor in Computer-Aided Drug Design
Athanasios Typas
Group Leader & Senior Scientist, European Molecular Biology Laboratory
Bernhard Kerscher
Head of Laboratory & Preclinical Assessor, Paul-Ehrlich-Institut - German Federal Institute for Vaccines and Biomedicines
Betsy Wonderly Trainor
Alliance Director Diagnostics, CARB-X
Bita Sehat
Senior Investment Director, Trill Impact
Chantal Morel
Health economist in anti-microbial resistance, KPM Center for Public Management, University of Bern
Christoph Dehio
Full Professor of Molecular Microbiology, Director of National Centre of Competence in Research (NCCR) “AntiResist”
Deborah O’Neil
CEO, NovaBiotics Ltd & Board Member, BEAM Alliance
Dominic O’Neil
Director Microbiome Product Development, QIAGEN GmbH
Douglas Häggström
Manager INCATE, University of Basel
Ed Buurman
Alliance Director CARB-X
Giancarlo Biagini
Head of the Department of Tropical Disease Biology, Liverpool School of Tropical Medicine
Glenn E. Dale
Chief Development Officer, BioVersys AG
Hasan Jafri
Chief Medical Officer, Aridis Pharmaceuticals Inc.
Jan Poolman
Vice-President, Head Bacterial Vaccine Discovery and Early Development, Janssen Vaccines & Prevention B.V.
John Alter
Head of External Affairs, AMR Action Fund
John Rex
Chief Medical Officer, F2G Ltd. & Operating Partner, Advent Life Sciences
Kevin Outterson
Austin B Fletcher Professor, Boston University, and Executive Director & Principal Investigator, CARB-X
Marc Gitzinger
CEO, BioVersys AG & Vice President, BEAM Alliance
Maria Uria-Nickelsen
Alliance Director, CARB-X
Mark Jones, PhD PMP
Head of Development, Basilea Pharmaceutica International Ltd | BEAM Alliance - Board Member | Swiss Round Table for Antibiotics - Board Member
Marlieke De Kraker
Senior epidemiologist, Geneva University Hospitals and Faculty of Medicine
Martin Heidecker
Chief Investment Officer, AMR Action Fund
Martin J. Boeree
Professor in clinical tuberculosis, Radboud universitair medisch centrum
Morgane Vanbiervliet
Manager, Market Intelligence & Business Development, Infectious Diseases, Debiopharm International SA
Peter Jackson
Executive director, Infex Therapeutics
Rachel Silverman Bonnifield
Senior Fellow, Center for Global Development
Rakel Arrazuria
Researcher, Microbiology Division, Paul-Ehrlich-Institut - German Federal Institute for Vaccines and Biomedicines
Ralf Sudbrak
Interim Secretariat Lead, Global AMR R&D Hub
Remko van Leeuwen
Chief Executive Officer, Madam Therapeutics
Shampa Das
Deputy Head of Department of Pharmacology and Therapeutics, University of Liverpool
Su Chiang
Senior Alliance Manager, CARB-X, Boston University
Taslimarif Saiyed
Director and CEO, Centre for Cellular and Molecular Platforms
Urs Jenal
Professor of Infection Biology, University of Basel & Co-director of NCCR AntiResist
Wolfgang Philipp
Acting Deputy Head HERA, European Commission
Yann Ferrisse
Director, Business Development & Partner Engagement, GARDP Foundation
Zemer Gitai
EG Conklin Professor, Department of Molecular Biology, Princeton University and Founder, ArrePath Inc.
More speaker profiles will be published soon.